Douglas E. Wright
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Douglas E. Wright has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
Janelle M. Ryals
Departments of Anesthesiology
17 shared publicationsJonathan Enders
Department of Anesthesiology, University of Kansas Medical Center, Kansas City, Kansas, USA
5 shared publications- Julie A. Christianson
University of Kansas Medical Center
5 shared publications Sarah Thomas
Departments of Anesthesiology
5 shared publicationsCaleb W. Grote
Department of Orthopedic Surgery, University of Kansas Medical Center, United States
3 shared publicationsJ. M. Ryals
Department of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA
3 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 18, 1854989
Small-fiber degeneration, sensory dysfunction, and nociception comorbidity in central neurodegenerative disease
Progressive neurodegenerative disease typically calls for clinical effort to improve cognitive and motor deficits. It is also focused on improving patients' quality of life. However, across these dementias and other diseases, the underlying causes and potential mechanisms remain unclear. Most experimental and clinical research focuses on the central nervous system, examining pathogenic proteins such as tau and amyloid beta, as well as the potential cascade following mitochondrial damage and neuroinflammation. Although peripheral involvement, including gut microbiome influences and other visceral organs, is well-documented, the peripheral nervous system remains an understudied component of these progressive diseases. As peripheral terminals of primary afferent neurons are exposed to inflammatory or toxic mediators, these neurons respond to these threats via neuron-specific phenotypic changes, including the generation of pain. Although normal peripheral sensitization is protective, exposure to damage in a chronic disease state can have long-term detrimental effects. Diseases that lead to central neurodegeneration often also feature peripheral neuropathy and chronic pain. We provide an overview of the incidence of peripheral neuropathy within these diseases, the contribution of changes in sensation to disease, and secondary neuropathic phenotypes resulting from disease. Woven in are discussions of the intersection of degeneration and toxic protein aggregation, briefly touching on resulting inflammatory signaling. Altogether, this review aims to synthesize current understanding of sensory peripheral nerve involvement across these neurodegenerative diseases.
- 21 October 2026
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 18, 1854989
Open AccessSmall-fiber degeneration, sensory dysfunction, and nociception comorbidity in central neurodegenerative disease
Progressive neurodegenerative disease typically calls for clinical effort to improve cognitive and motor deficits. It is also focused on improving patients' quality of life. However, across these dementias and other diseases, the underlying causes and potential mechanisms remain unclear. Most experimental and clinical research focuses on the central nervous system, examining pathogenic proteins such as tau and amyloid beta, as well as the potential cascade following mitochondrial damage and neuroinflammation. Although peripheral involvement, including gut microbiome influences and other visceral organs, is well-documented, the peripheral nervous system remains an understudied component of these progressive diseases. As peripheral terminals of primary afferent neurons are exposed to inflammatory or toxic mediators, these neurons respond to these threats via neuron-specific phenotypic changes, including the generation of pain. Although normal peripheral sensitization is protective, exposure to damage in a chronic disease state can have long-term detrimental effects. Diseases that lead to central neurodegeneration often also feature peripheral neuropathy and chronic pain. We provide an overview of the incidence of peripheral neuropathy within these diseases, the contribution of changes in sensation to disease, and secondary neuropathic phenotypes resulting from disease. Woven in are discussions of the intersection of degeneration and toxic protein aggregation, briefly touching on resulting inflammatory signaling. Altogether, this review aims to synthesize current understanding of sensory peripheral nerve involvement across these neurodegenerative diseases.
- Open Access
- 17 February 2026
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 11 (2)
Neuronal metabolism role in ketogenic diet improvements in bortezomib-induced painful peripheral neuropathy mouse model
Introduction: A ketogenic diet (KD) can benefit a range of neurological conditions, including different types of peripheral neuropathy. Bortezomib (BTZ), a first-line chemotherapy for treating multiple myeloma, has neurotoxic effects and often induces chemotherapy-induced peripheral neuropathy. Objectives: Here, we tested whether a KD could prevent the onset of small fiber neuropathy and behavioral hypersensitivity associated with bortezomib-induced peripheral neuropathy (BIPN). Methods: Male C57BL/6 mice were fed either a standard chow diet or a KD for 10 days. During the first 5 days of KD administration, mice received daily intraperitoneal injections of BTZ or vehicle. Mice entered a BTZ washout period on day 6 while remaining on their specific diets. Hindpaw responses to mechanical (von Frey) and cold (acetone) stimuli were measured to determine how KD and BTZ treatment affected behavioral sensitivity. Footpads were harvested for analysis of intraepidermal nerve fiber density (IENFD), and lumbar dorsal root ganglia were collected for in vitro analysis of neurite outgrowth and cellular bioenergetics. Results: Bortezomib-treated, KD-fed mice exhibited decreased mechanical hypersensitivity, normalized cold hypersensitivity, preserved IENFD, and decreased extracellular acidification rate compared with BTZ-treated, chow-fed mice. In vitro analysis of ketones' ability to protect against BTZ-induced reductions in neurite growth revealed that cultured neurons pretreated with ketones were protected from BTZ-induced neurite degeneration. Conclusion: Findings suggest that KD protects against reductions in IENFD, behavioral hypersensitivity, and bioenergetic shifts induced by BIPN, and provides evidence that KD provides protection against BTZ and could be a potential therapeutic for BIPN.
- 17 February 2026
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 11 (2)
Open AccessNeuronal metabolism role in ketogenic diet improvements in bortezomib-induced painful peripheral neuropathy mouse model
Introduction: A ketogenic diet (KD) can benefit a range of neurological conditions, including different types of peripheral neuropathy. Bortezomib (BTZ), a first-line chemotherapy for treating multiple myeloma, has neurotoxic effects and often induces chemotherapy-induced peripheral neuropathy. Objectives: Here, we tested whether a KD could prevent the onset of small fiber neuropathy and behavioral hypersensitivity associated with bortezomib-induced peripheral neuropathy (BIPN). Methods: Male C57BL/6 mice were fed either a standard chow diet or a KD for 10 days. During the first 5 days of KD administration, mice received daily intraperitoneal injections of BTZ or vehicle. Mice entered a BTZ washout period on day 6 while remaining on their specific diets. Hindpaw responses to mechanical (von Frey) and cold (acetone) stimuli were measured to determine how KD and BTZ treatment affected behavioral sensitivity. Footpads were harvested for analysis of intraepidermal nerve fiber density (IENFD), and lumbar dorsal root ganglia were collected for in vitro analysis of neurite outgrowth and cellular bioenergetics. Results: Bortezomib-treated, KD-fed mice exhibited decreased mechanical hypersensitivity, normalized cold hypersensitivity, preserved IENFD, and decreased extracellular acidification rate compared with BTZ-treated, chow-fed mice. In vitro analysis of ketones' ability to protect against BTZ-induced reductions in neurite growth revealed that cultured neurons pretreated with ketones were protected from BTZ-induced neurite degeneration. Conclusion: Findings suggest that KD protects against reductions in IENFD, behavioral hypersensitivity, and bioenergetic shifts induced by BIPN, and provides evidence that KD provides protection against BTZ and could be a potential therapeutic for BIPN.
- Open Access
- 29 October 2025
- Published by Elsevier in Neuroscience
- Vol. 589, 268-279
TLR4 deletion reduces small fiber sensory abnormalities and nerve degeneration in diabetic male mice
- 29 October 2025
- Published by Elsevier in Neuroscience
- Vol. 589, 268-279
Open AccessTLR4 deletion reduces small fiber sensory abnormalities and nerve degeneration in diabetic male mice
- 1 July 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 329 (1) , C31-C37
Modulation of pain by ketones: a mini-review
Ketones, or ketone bodies, are organic molecules produced via ketogenesis in the liver in response to changing energy demands. Three ketones are generated that can act as metabolic messengers and a fuel source for the body, typically forming when glucose levels decrease within the bloodstream. A ketogenic diet, a form of low-carbohydrate, high-fat diet, stimulates ketogenesis and forces ketone utilization as an energy source by nonhepatic tissues. Currently, ketones, along with the ketogenic diet, have been of interest to many as a therapeutic mechanism for multiple conditions, including epilepsy, numerous neurodegenerative diseases, and diabetes. Emerging preclinical evidence suggests that ketones may play a powerful role in modulating acute and chronic pain. Here, we summarize the known benefits of ketones on neurological disease and nociceptive systems associated with pain. We discuss possible mechanisms identified from preclinical studies underlying the identified benefits of ketones in reducing pain.
- 1 July 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 329 (1) , C31-C37
Modulation of pain by ketones: a mini-review
Ketones, or ketone bodies, are organic molecules produced via ketogenesis in the liver in response to changing energy demands. Three ketones are generated that can act as metabolic messengers and a fuel source for the body, typically forming when glucose levels decrease within the bloodstream. A ketogenic diet, a form of low-carbohydrate, high-fat diet, stimulates ketogenesis and forces ketone utilization as an energy source by nonhepatic tissues. Currently, ketones, along with the ketogenic diet, have been of interest to many as a therapeutic mechanism for multiple conditions, including epilepsy, numerous neurodegenerative diseases, and diabetes. Emerging preclinical evidence suggests that ketones may play a powerful role in modulating acute and chronic pain. Here, we summarize the known benefits of ketones on neurological disease and nociceptive systems associated with pain. We discuss possible mechanisms identified from preclinical studies underlying the identified benefits of ketones in reducing pain.
- Open Access
ATP-Gated Potassium Channels Contribute to Ketogenic Diet-Mediated Analgesia in Mice
Chronic pain is a substantial health burden and options for treating chronic pain remain minimally effective. Ketogenic diets are emerging as well-tolerated, effective therapeutic strategies in preclinical models of chronic pain, especially diabetic neuropathy. We tested whether a ketogenic diet is antinociceptive through ketone oxidation and related activation of ATP-gated potassium (K ATP ) channels in mice. We demonstrate that consumption of a ketogenic diet for one week reduced evoked nocifensive behaviors (licking, biting, lifting) following intraplantar injection of different noxious stimuli (methylglyoxal, cinnamaldehyde, capsaicin, or Yoda1) in mice. A ketogenic diet also decreased the expression of p-ERK, an indicator of neuronal activation in the spinal cord, following peripheral administration of these stimuli. Using a genetic mouse model with deficient ketone oxidation in peripheral sensory neurons, we demonstrate that protection against methylglyoxal-induced nociception by a ketogenic diet partially depends on ketone oxidation by peripheral neurons. Injection of tolbutamide, a K ATP channel antagonist, prevented ketogenic diet-mediated antinociception following intraplantar capsaicin injection. Tolbutamide also restored the expression of spinal activation markers in ketogenic diet-fed, capsaicin-injected mice. Moreover, activation of K ATP channels with the K ATP channel agonist diazoxide reduced pain-like behaviors in capsaicin-injected, chow-fed mice, similar to the effects observed with a ketogenic diet. Diazoxide also reduced the number of p-ERK + cells in capsaicin-injected mice. These data support a mechanism that includes neuronal ketone oxidation and activation of K ATP channels to provide ketogenic diet-related analgesia. This study also identifies K ATP channels as a new target to mimic the antinociceptive effects of a ketogenic diet.
Open AccessATP-Gated Potassium Channels Contribute to Ketogenic Diet-Mediated Analgesia in Mice
Chronic pain is a substantial health burden and options for treating chronic pain remain minimally effective. Ketogenic diets are emerging as well-tolerated, effective therapeutic strategies in preclinical models of chronic pain, especially diabetic neuropathy. We tested whether a ketogenic diet is antinociceptive through ketone oxidation and related activation of ATP-gated potassium (K ATP ) channels in mice. We demonstrate that consumption of a ketogenic diet for one week reduced evoked nocifensive behaviors (licking, biting, lifting) following intraplantar injection of different noxious stimuli (methylglyoxal, cinnamaldehyde, capsaicin, or Yoda1) in mice. A ketogenic diet also decreased the expression of p-ERK, an indicator of neuronal activation in the spinal cord, following peripheral administration of these stimuli. Using a genetic mouse model with deficient ketone oxidation in peripheral sensory neurons, we demonstrate that protection against methylglyoxal-induced nociception by a ketogenic diet partially depends on ketone oxidation by peripheral neurons. Injection of tolbutamide, a K ATP channel antagonist, prevented ketogenic diet-mediated antinociception following intraplantar capsaicin injection. Tolbutamide also restored the expression of spinal activation markers in ketogenic diet-fed, capsaicin-injected mice. Moreover, activation of K ATP channels with the K ATP channel agonist diazoxide reduced pain-like behaviors in capsaicin-injected, chow-fed mice, similar to the effects observed with a ketogenic diet. Diazoxide also reduced the number of p-ERK + cells in capsaicin-injected mice. These data support a mechanism that includes neuronal ketone oxidation and activation of K ATP channels to provide ketogenic diet-related analgesia. This study also identifies K ATP channels as a new target to mimic the antinociceptive effects of a ketogenic diet.
- 3 May 2023
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 38 (13-15) , 989-1000
Emerging Nonpharmacologic Interventions to Treat Diabetic Peripheral Neuropathy
Significance: Diabetic peripheral neuropathy (DPN), a complication of metabolic syndrome, type I and type II diabetes, leads to sensory changes that include slow nerve conduction, nerve degeneration, loss of sensation, pain, and gate disturbances. These complications remain largely untreatable, although tight glycemic control can prevent neuropathy progression. Nonpharmacologic approaches remain the most impactful to date, but additional advances in treatment approaches are needed. Recent Advances: This review highlights several emerging interventions, including a focus on dietary interventions and physical activity, that continue to show promise for treating DPN. We provide an overview of our current understanding of how exercise can improve aspects of DPN. We also highlight new studies in which a ketogenic diet has been used as an intervention to prevent and reverse DPN. Critical Issues: Both exercise and consuming a ketogenic diet induce systemic and cellular changes that collectively improve complications associated with DPN. Both interventions may involve similar signaling pathways and benefits but also impact DPN through unique mechanisms. Future Directions: These lifestyle interventions are critically important as personalized medicine approaches will likely be needed to identify specific subsets of neuropathy symptoms and deficits in patients, and determine the most impactful treatment. Overall, these two interventions have the potential to provide meaningful relief for patients with DPN and provide new avenues to identify new therapeutic targets.
- 3 May 2023
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 38 (13-15) , 989-1000
Emerging Nonpharmacologic Interventions to Treat Diabetic Peripheral Neuropathy
Significance: Diabetic peripheral neuropathy (DPN), a complication of metabolic syndrome, type I and type II diabetes, leads to sensory changes that include slow nerve conduction, nerve degeneration, loss of sensation, pain, and gate disturbances. These complications remain largely untreatable, although tight glycemic control can prevent neuropathy progression. Nonpharmacologic approaches remain the most impactful to date, but additional advances in treatment approaches are needed. Recent Advances: This review highlights several emerging interventions, including a focus on dietary interventions and physical activity, that continue to show promise for treating DPN. We provide an overview of our current understanding of how exercise can improve aspects of DPN. We also highlight new studies in which a ketogenic diet has been used as an intervention to prevent and reverse DPN. Critical Issues: Both exercise and consuming a ketogenic diet induce systemic and cellular changes that collectively improve complications associated with DPN. Both interventions may involve similar signaling pathways and benefits but also impact DPN through unique mechanisms. Future Directions: These lifestyle interventions are critically important as personalized medicine approaches will likely be needed to identify specific subsets of neuropathy symptoms and deficits in patients, and determine the most impactful treatment. Overall, these two interventions have the potential to provide meaningful relief for patients with DPN and provide new avenues to identify new therapeutic targets.
- 24 April 2023
- Published by Elsevier in Experimental Neurology
- Vol. 365, 114428
Ketolysis is required for the proper development and function of the somatosensory nervous system
- 24 April 2023
- Published by Elsevier in Experimental Neurology
- Vol. 365, 114428
Ketolysis is required for the proper development and function of the somatosensory nervous system
- Open Access
- 20 April 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14
Abnormal intraepidermal nerve fiber density in disease: A scoping review
Background: Intraepidermal nerve fiber density (IENFD) has become an important biomarker for neuropathy diagnosis and research. The consequences of reduced IENFD can include sensory dysfunction, pain, and a significant decrease in quality of life. We examined the extent to which IENFD is being used as a tool in human and mouse models and compared the degree of fiber loss between diseases to gain a broader understanding of the existing data collected using this common technique.Methods: We conducted a scoping review of publications that used IENFD as a biomarker in human and non-human research. PubMed was used to identify 1,004 initial articles that were then screened to select articles that met the criteria for inclusion. Criteria were chosen to standardize publications so they could be compared rigorously and included having a control group, measuring IENFD in a distal limb, and using protein gene product 9.5 (PGP9.5).Results: We analyzed 397 articles and collected information related to publication year, the condition studied, and the percent IENFD loss. The analysis revealed that the use of IENFD as a tool has been increasing in both human and non-human research. We found that IENFD loss is prevalent in many diseases, and metabolic or diabetes-related diseases were the most studied conditions in humans and rodents. Our analysis identified 73 human diseases in which IENFD was affected, with 71 reporting IENFD loss and an overall average IENFD change of −47%. We identified 28 mouse and 21 rat conditions, with average IENFD changes of −31.6% and −34.7%, respectively. Additionally, we present data describing sub-analyses of IENFD loss according to disease characteristics in diabetes and chemotherapy treatments in humans and rodents.Interpretation: Reduced IENFD occurs in a surprising number of human disease conditions. Abnormal IENFD contributes to important complications, including poor cutaneous vascularization, sensory dysfunction, and pain. Our analysis informs future rodent studies so they may better mirror human diseases impacted by reduced IENFD, highlights the breadth of diseases impacted by IENFD loss, and urges exploration of common mechanisms that lead to substantial IENFD loss as a complication in disease.
- 20 April 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14
Open AccessAbnormal intraepidermal nerve fiber density in disease: A scoping review
Background: Intraepidermal nerve fiber density (IENFD) has become an important biomarker for neuropathy diagnosis and research. The consequences of reduced IENFD can include sensory dysfunction, pain, and a significant decrease in quality of life. We examined the extent to which IENFD is being used as a tool in human and mouse models and compared the degree of fiber loss between diseases to gain a broader understanding of the existing data collected using this common technique.Methods: We conducted a scoping review of publications that used IENFD as a biomarker in human and non-human research. PubMed was used to identify 1,004 initial articles that were then screened to select articles that met the criteria for inclusion. Criteria were chosen to standardize publications so they could be compared rigorously and included having a control group, measuring IENFD in a distal limb, and using protein gene product 9.5 (PGP9.5).Results: We analyzed 397 articles and collected information related to publication year, the condition studied, and the percent IENFD loss. The analysis revealed that the use of IENFD as a tool has been increasing in both human and non-human research. We found that IENFD loss is prevalent in many diseases, and metabolic or diabetes-related diseases were the most studied conditions in humans and rodents. Our analysis identified 73 human diseases in which IENFD was affected, with 71 reporting IENFD loss and an overall average IENFD change of −47%. We identified 28 mouse and 21 rat conditions, with average IENFD changes of −31.6% and −34.7%, respectively. Additionally, we present data describing sub-analyses of IENFD loss according to disease characteristics in diabetes and chemotherapy treatments in humans and rodents.Interpretation: Reduced IENFD occurs in a surprising number of human disease conditions. Abnormal IENFD contributes to important complications, including poor cutaneous vascularization, sensory dysfunction, and pain. Our analysis informs future rodent studies so they may better mirror human diseases impacted by reduced IENFD, highlights the breadth of diseases impacted by IENFD loss, and urges exploration of common mechanisms that lead to substantial IENFD loss as a complication in disease.
- 21 March 2023
- Published by Springer Nature
- p. 397-414
Lifestyle and Dietary Modifications: Relevance in the Management of Diabetic Neuropathy
- 21 March 2023
- Published by Springer Nature
- p. 397-414
Lifestyle and Dietary Modifications: Relevance in the Management of Diabetic Neuropathy
- Open Access
Ketolysis is Required for the Proper Development and Function of the Somatosensory Nervous System
Ketogenic diets are emerging as protective interventions in preclinical and clinical models of somatosensory nervous system disorders. Additionally, dysregulation of succinyl-CoA 3-oxoacid CoA-transferase 1 (SCOT, encoded by Oxct1 ), the fate-committing enzyme in mitochondrial ketolysis, has recently been described in Friedreich’s ataxia and amyotrophic lateral sclerosis. However, the contribution of ketone metabolism in the normal development and function of the somatosensory nervous system remains poorly characterized. We generated sensory neuron-specific, Advillin-Cre knockout of SCOT (Adv-KO-SCOT) mice and characterized the structure and function of their somatosensory system. We used histological techniques to assess sensory neuronal populations, myelination, and skin and spinal dorsal horn innervation. We also examined cutaneous and proprioceptive sensory behaviors with the von Frey test, radiant heat assay, rotarod, and grid-walk tests. Adv-KO-SCOT mice exhibited myelination deficits, altered morphology of putative Aδ soma from the dorsal root ganglion, reduced cutaneous innervation, and abnormal innervation of the spinal dorsal horn compared to wildtype mice. Synapsin 1-Cre-driven knockout of Oxct1 confirmed deficits in epidermal innervation following a loss of ketone oxidation. Loss of peripheral axonal ketolysis was further associated with proprioceptive deficits, yet Adv-KO-SCOT mice did not exhibit drastically altered cutaneous mechanical and thermal thresholds. Knockout of Oxct1 in peripheral sensory neurons resulted in histological abnormalities and severe proprioceptive deficits in mice. We conclude that ketone metabolism is essential for the development of the somatosensory nervous system. These findings also suggest that decreased ketone oxidation in the somatosensory nervous system may explain the neurological symptoms of Friedreich’s ataxia.
Open AccessKetolysis is Required for the Proper Development and Function of the Somatosensory Nervous System
Ketogenic diets are emerging as protective interventions in preclinical and clinical models of somatosensory nervous system disorders. Additionally, dysregulation of succinyl-CoA 3-oxoacid CoA-transferase 1 (SCOT, encoded by Oxct1 ), the fate-committing enzyme in mitochondrial ketolysis, has recently been described in Friedreich’s ataxia and amyotrophic lateral sclerosis. However, the contribution of ketone metabolism in the normal development and function of the somatosensory nervous system remains poorly characterized. We generated sensory neuron-specific, Advillin-Cre knockout of SCOT (Adv-KO-SCOT) mice and characterized the structure and function of their somatosensory system. We used histological techniques to assess sensory neuronal populations, myelination, and skin and spinal dorsal horn innervation. We also examined cutaneous and proprioceptive sensory behaviors with the von Frey test, radiant heat assay, rotarod, and grid-walk tests. Adv-KO-SCOT mice exhibited myelination deficits, altered morphology of putative Aδ soma from the dorsal root ganglion, reduced cutaneous innervation, and abnormal innervation of the spinal dorsal horn compared to wildtype mice. Synapsin 1-Cre-driven knockout of Oxct1 confirmed deficits in epidermal innervation following a loss of ketone oxidation. Loss of peripheral axonal ketolysis was further associated with proprioceptive deficits, yet Adv-KO-SCOT mice did not exhibit drastically altered cutaneous mechanical and thermal thresholds. Knockout of Oxct1 in peripheral sensory neurons resulted in histological abnormalities and severe proprioceptive deficits in mice. We conclude that ketone metabolism is essential for the development of the somatosensory nervous system. These findings also suggest that decreased ketone oxidation in the somatosensory nervous system may explain the neurological symptoms of Friedreich’s ataxia.